A Pharmacokinetics Study to Assess the Oral Administration of CB7630 (Abiraterone Acetate) Capsule Formulation and Tablet Formulation in Patients With Prostate Cancer

Inclusion Criteria:

- Men with histologically, cytologically, or biochemically confirmed adenocarcinoma of
the prostate

- On-going androgen deprivation with serum testosterone <50 ng/dL (<2.0nmol/L)

- Serum potassium >=3.5 mmol/L

- Eastern Cooperative Oncology Group (ECOG) Performance Status score <2 (Karnofsky
Performance Status >=50%)

- No history of adrenal insufficiency or hyperaldosteronism

- Any acute toxicities of prior chemotherapy, radiotherapy have resolved to a NCI CTCAE
(version 3.0) grade of <=1 (chemotherapy induced alopecia and grade 2 neuropathy are
excluded from this consideration)

- No radiotherapy, chemotherapy, or immunotherapy within 30 days of administration of
the study drug 1 (SD1) on Day 1

- No surgery or local prostatic intervention within 28 days of the first dose (any
clinically relevant sequelae from the surgery must have resolved prior to SD1 on Day
1)

- Agrees to protocol-defined use of effective contraception

- Life expectancy >12 weeks

Exclusion Criteria:

- Active or uncontrolled autoimmune disease that may require corticosteroid therapy

- Serious or uncontrolled co-existent non-malignant disease, including active and
uncontrolled infection

- Uncontrolled hypertension

- Protocol-defined laboratory values

- Clinically significant heart disease as evidenced by a myocardial infarction in the
past 12 months, severe or unstable angina, or New York Heart Association (NYHA) Class
III or IV heart disease (patients with a history of atherosclerotic vascular disease
requiring coronary or peripheral artery bypass surgery may be enrolled provided the
surgery occurred at least 2 years prior to enrollment and after consultation with a
cardiologist to insure that the disease is stable)

- Other malignancy within the previous 5-years other than basal cell or squamous cell
carcinomas of skin with a >30% probability of recurrence within 12 months

- History of gastrointestinal disorders (medical disorders or extensive surgery) which
may interfere with the absorption of the study medication

- Condition or situation which, in the investigator's opinion, may put the patient at
significant risk, may confound the study results, or may interfere significantly with
patient's participation in the study